Interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 67, Issue 12, 2015, Pages 3219-3225

  Rudloff, Ina ^a   Godsell, Jack ^a   Nold Petry, Claudia A ^a   Harris, James ^a   Hoi, Alberta ^a   Morand, Eric F ^a   Nold, Marcel F ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; APRIL PROTEIN; AZATHIOPRINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 38; INTERLEUKIN 6; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID; PREDNISOLONE; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 38; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CCL2 PROTEIN, HUMAN; IL-38 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN VASCULITIS; CELL STIMULATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED PRACTICE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; GENE SILENCING; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; MONONUCLEAR CELL; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHEMOKINE CCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; RNA, SMALL INTERFERING; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; YOUNG ADULT;

EID: 84948419437     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39328     Document Type: Article

References (19)

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al., Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308.
2. Liu Z, Davidson A., Taming lupus: a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012; 18: 871-82.
3. Davis LS, Hutcheson J, Mohan C., The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31: 781-9.
4. Vincent F, Northcott M, Hoi A, Mackay F, Morand EF., Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther 2013; 15: R97.
5. Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF., Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013; 22: 873-84.
6. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA., IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010; 11: 1014-22.
7. Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O'Neill L, et al., IL-1 family nomenclature. Nat Immunol 2010; 11: 973.
8. Van de Veerdonk FL, Netea MG., New insights in the immunobiology of IL-1 family members. Front Immunol 2013; 4: 167.
9. Van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, et al., IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 2012; 109: 3001-5.
10. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, et al., Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011; 123: 731-8.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
12. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
13. Gladman DD, Ibanez D, Urowitz MB., Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288-91.
14. Nikpour M, Urowitz MB, Ibanez D, Gladman DD., Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1152-8.
15. Ibanez D, Gladman DD, Urowitz MB., Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005; 32: 824-7.
16. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al., The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9.
17. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
18. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY., Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119: 296-305.
19. Brugos B, Kiss E, Dul C, Gubisch W, Szegedi G, Sipka S, et al., Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Hum Immunol 2010; 71: 874-7.